UMR 216, Institut de Recherche pour le Développement and Université Paris Descartes, Paris, France.
PLoS One. 2013;8(3):e59446. doi: 10.1371/journal.pone.0059446. Epub 2013 Mar 15.
To investigate the factors associated with HIV1 RNA plasma viral load (pVL) below 40 copies/mL at the third trimester of pregnancy, as part of prevention of mother-to-child transmission (PMTCT) in Benin.
Sub study of the PACOME clinical trial of malaria prophylaxis in HIV-infected pregnant women, conducted before and after the implementation of the WHO 2009 revised guidelines for PMTCT.
HIV-infected women were enrolled in the second trimester of pregnancy. Socio-economic characteristics, HIV history, clinical and biological characteristics were recorded. Malaria prevention and PMTCT involving antiretroviral therapy (ART) for mothers and infants were provided. Logistic regression helped identifying factors associated with virologic suppression at the end of pregnancy.
Overall 217 third trimester pVLs were available, and 71% showed undetectability. Virologic suppression was more frequent in women enrolled after the change in PMTCT recommendations, advising to start ART at 14 weeks instead of 28 weeks of pregnancy. In multivariate analysis, Fon ethnic group (the predominant ethnic group in the study area), regular job, first and second pregnancy, higher baseline pVL and impaired adherence to ART were negative factors whereas higher weight, higher antenatal care attendance and longer ART duration were favorable factors to achieve virologic suppression.
This study provides more evidence that ART has to be initiated before the last trimester of pregnancy to achieve an undetectable pVL before delivery. In Benin, new recommendations supporting early initiation were well implemented and, together with a high antenatal care attendance, led to high rate of virologic control.
研究贝宁母婴传播预防(PMTCT)中与孕妇妊娠晚期 HIV1 RNA 血浆病毒载量(pVL)低于 40 拷贝/毫升相关的因素。
在实施世界卫生组织 2009 年修订的 PMTCT 指南前后,作为疟疾预防 PACOME 临床试验的子研究。
HIV 感染的孕妇在妊娠中期入组。记录社会经济特征、HIV 病史、临床和生物学特征。提供疟疾预防和涉及母亲和婴儿抗逆转录病毒治疗(ART)的 PMTCT。逻辑回归有助于确定与妊娠期末病毒学抑制相关的因素。
共有 217 份第三孕期 pVL 可用,其中 71% 不可检测。在改变 PMTCT 建议后入组的女性中,病毒学抑制更为频繁,建议在妊娠 14 周而不是 28 周开始 ART。多变量分析表明,Fon 族(研究地区的主要族群)、固定工作、第一和第二胎、较高的基线 pVL 和 ART 依从性受损是负面因素,而较高的体重、较高的产前护理就诊次数和较长的 ART 持续时间是实现病毒学抑制的有利因素。
这项研究提供了更多证据表明,ART 必须在妊娠晚期之前开始,以便在分娩前达到不可检测的 pVL。在贝宁,支持早期启动的新建议得到了很好的实施,加上较高的产前护理就诊率,导致了较高的病毒学控制率。